Robey Rebecca C, Mletzko Salvinia, Gotch Frances M
Department of Immunology, Imperial College London, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK.
Adv Virol. 2010;2010:340356. doi: 10.1155/2010/340356. Epub 2011 Jan 16.
Kaposi's sarcoma-associated herpesvirus (KSHV) is the aetiological agent of Kaposi's sarcoma (KS), the most frequently arising malignancy in individuals with untreated HIV/AIDS. There are several lines of evidence to indicate that Kaposi's sarcoma oncogenesis is associated with loss of T-cell-mediated control of KSHV-infected cells. KSHV can establish life-long asymptomatic infection in immune-competent individuals. However, when T-cell immune control declines, for example, through AIDS or treatment with immunosuppressive drugs, both the prevalence of KSHV infection and the incidence of KS in KSHV carriers dramatically increase. Moreover, a dramatic and spontaneous improvement in KS is frequently seen when immunity is restored, for example, through antiretroviral therapy or the cessation of iatrogenic drugs. In this paper we describe the current state of knowledge on the T-cell immune responses against KSHV.
卡波西肉瘤相关疱疹病毒(KSHV)是卡波西肉瘤(KS)的病原体,卡波西肉瘤是未接受治疗的HIV/AIDS患者中最常见的恶性肿瘤。有几条证据表明,卡波西肉瘤的肿瘤发生与T细胞介导的对KSHV感染细胞的控制丧失有关。KSHV可在免疫功能正常的个体中建立终身无症状感染。然而,当T细胞免疫控制下降时,例如通过艾滋病或使用免疫抑制药物进行治疗,KSHV感染的患病率和KSHV携带者中KS的发病率都会显著增加。此外,当免疫力恢复时,例如通过抗逆转录病毒治疗或停止医源性药物治疗,KS通常会出现显著且自发的改善。在本文中,我们描述了目前关于针对KSHV的T细胞免疫反应的知识状况。